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Abstract
Background: Over the past decades, the increase in maximal cell numbers for the production of
mammalian derived biologics has been in a large part due to the development of optimal feeding
strategies. Engineering of the cell line is one of probable approaches for increasing cell numbers in
bioreactor.
Results: We have demonstrated that the over-expression of the c-myc gene in immortalised CHO
cells can increase proliferation rate and maximal cell density in batch culture compared to the
control. The changes were attributed to a rapid transition into S-phase from a shortened duration
of G1 phase and to the uncoupling of cell size from cell proliferation. To achieve the >70% increase
in maximal cell density without additional supply of nutrients the cells underwent an overall
reduction of 14% in size as well as a significant decrease in glucose and amino acid consumption
rate. Consequently, the total biomass accumulation did not show a significant change from the
control. The amount of hSEAP-hFc activity of the over expressing c-myc cell line was found to be
within 0.7% of the control.
Conclusion: It is shown that the manipulation of cell cycle kinetics and indirectly cell metabolism
gives higher cell densities in CHO batch cultures. The unaltered apoptotic rate supported the
proposition that the increase in cell number was a result of enhance cell cycle kinetics and cellular
metabolism rather than increasing viability. Production of hSEAP-hFc from a constitutive c-myc
over-expressing cell line did not increase with the increase in cell number.
Background
The Chinese Hamster Ovary (CHO) cell line is the work-
horse of the bioprocessing industry for the production of
biopharmaceuticals. The high productivity of the cell line
in bioreactors can be said to be dependent on having a
high viable cell density of rapidly dividing cells over an
extended period of time. The relatively high cell numbers
achieved over more than two decades of process optimi-
zation strategies utilising media and fed batch cultivation
improvements [1,2] resulted in product titres of more
than 5 g/l.
In biopharmaceutical production systems, optimisation
of cell culture processes is an evolving field as the more we
understand of the complex dynamics involved in regulat-
ing cell survival, growth and productivity, the better we
can apply this knowledge to improve titre. Cell engineer-
ing strategies to improve maximal cell number would be
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a major step towards reaching the goal of increased prod-
uct titre. The use of c-Myc has been recently put forward as
a possible means of achieving this goal [3,4], but a more
thorough understanding is needed to explain the role of c-
myc in the CHO-K1 immortalised continuous cell line.
Particularly, as a key regulator of the cell cycle and to pro-
vide a rationale for the experimental observation that the
cell size seems to play an important role in establishing an
increased cell number, before it can be incorporated into
cell lines that are used for the production of therapeutic
protein at industrial scale.
The product of c-myc is a nuclear phosphoprotein that has
been implicated in cell cycle progression and apoptosis,
although it is still unclear on how the protein carries out
its functions and is regulated [5]. It belongs to a family of
myc genes which was discovered as a cellular homologue
to the viral oncogene (v-myc) of the avian myelocytoma-
tosis MC29 retrovirus [6]. The nuclear phosphoprotein
has a short life of about 20-30 minutes [7]. Its physiolog-
ical role is based on the fact that its expression strongly
correlates with cellular proliferation and thus it has been
broadly expressed during embryogenesis and in tissue
compartments that contain high proliferative capacity
such as the mammalian gut and skin epidermis.
As a transcription factor, c-Myc binds to the promoters of
a large number of genes to regulate their expression, in
turn, controlling, the cell cycle, metabolic processes, mac-
romolecular synthesis and apoptosis[8]. In quiescent G0
cells, c-myc expression is almost undetectable until there is
some serum or mitogenic stimulation, which causes rapid
induction of cell transition into G1. After this transition, c-
Myc levels decline to a low but detectable level, while
removal of serum or mitogenic stimuli will again put c-
Myc into undetectable level and thus cellular arrest occurs.
Some known targets of c-Myc are cyclin D2 and CDK2
(essential in cell cycle regulation), and eIF4 and eIF2
which are important in cell growth[9].
In the past few years it has become apparent that c-myc
regulation is related somewhat to apoptotic pathways.
Pro-apoptotic pathways have been identified which con-
verges on the central mitochondrial induced apoptotic
pathway. This is due to the fact that c-myc over-expression
also affects the ARF/Mdm-2 pathway (ARF, a small pro-
tein from the INK4 family, binds to Mdm2 protein whose
function is to negatively regulate the activity of p53 pro-
tein) by promoting expression of ARF and thus up-regu-
lating p53 expression leading to apoptosis [10].
In immortalised continuous cell lines, such as CHO cell
line, net expansion of a clone is not only achieved by an
increased rate of proliferation but a decrease in the apop-
totic rate as well. The most widely held opinion on this is
that since the cell cycle and apoptotic pathways are cou-
pled through several sub-networked pathways, the induc-
tion of the cell cycle can sensitize the cell to apoptosis but
the apoptotic pathway is suppressed as long as the appro-
priate survival factors are available to the cell [8]. Earlier
findings have established a role for c-myc in apoptosis in
diverse settings through separate 'death priming' and
'death triggering' mechanisms in which 'death priming'
and mitogenic signals are coordinated [11].
The objective of this study is to provide data for further
understanding CHO cells with an increased proliferation
capacity. This work will focus on the cell cycle and meta-
bolic aspects of having a cell line reach higher viable cell
densities with increased proliferation under the same sup-
plemented media conditions. Since the variability of
clones would not give further information related to this
objective, the original transfected population is used. For
the investigation into productivity clonal selection was
used to ensure a stable producer of hSEAP fusion protein.
Over-expression of c-myc has resulted in a reduced dura-
tion of the G1 phase of cell cycle thus leading to a reduced
growth rate and increased maximum cell number. This
change was associated with reduced glucose and amino
acid consumption rate and decreased cell size. The results
showed that the total volumetric biomass was negligibly
affected by c-myc over-expression and that without nutri-
ent addition any increase in cell number would be com-
pensated by a comparable decrease in cell volume.
Methods
All chemicals in the Materials and Methods section were
obtained from Sigma Aldrich unless stated otherwise.
Cell Transfection and Maintenance
The cMycCHO cell line resulted from calcium-mediated
stable transfection of CHO-K1 with the DORclaG123 (c-
Myc plasmid). The plasmid was kindly donated by Dr. T.
Littlewood (Imperial Cancer Research Fund, UK). The sur-
viving cells were pooled separately for each transfection
and were maintained in Ham's F12 supplemented with
5% FCS. Using dilution cloning a stable cMycCHO clone
was selected and used in subsequent experiments. A
detailed transfection and selection procedure is described
in a previous publication [3]. Selection pressure was
maintained by incubation in DMEM/F12, 4 mM L-
glutamine, 5% FBS (Lonza Biologics) and 1 mg/mL
geneticin G418 every 10th generation and cell samples
were taken before and after incubation to ensure stable
overexpression of the c-Myc protein. Selection pressure
was removed 2 passages before an experimental run to
negate the effects of the presence of antibiotic.
Static Batch Culture and Cell Size of CHO-K1 and 
cMycCHO
CHO-K1 and cMycCHO were maintained in DMEM/F12
with 5% FBS (Lonza Biologics, UK) and 4 mM L-BMC Biotechnology 2009, 9:76 http://www.biomedcentral.com/1472-6750/9/76
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glutamine at 37°C vented at 5% CO2. Static cultures from
each cell line were plated in 6 well plates, 80,000 cells/
cm2, with an initial density of 2 × 105 cells/ml allowing
triplicate cultures to be sacrificed at regular intervals for
each cell line. A duplicate culture was plated from the
experimental seeding inoculum for mid-exponential
phase harvesting to carry out the western analysis. When
harvesting cells, floating cells were collected by centrifuga-
tion of the aspirated medium, and adherent cells were
detached by Accutase™ and collected by centrifugation,
these were pooled together in a media volume equal to
the original culture volume before cell counts. Viable cell
concentration and viability were monitored using the
trypan blue exclusion method [12]. All cell volume meas-
urements were done using the coulter principle of elec-
tronic volume on a Quanta SC (Beckman Coulter) flow
cytometer which has forward scatter replaced by elec-
tronic volume.
Static Spent Media Cultures
The spent media was obtained from each respective cul-
ture to replicate conditions of supplement depletion. Each
cell line was seeded in T-25 flasks with 10 ml of the spent
media at 5 × 105 cells/ml at 37°C vented at 5% CO2. Cells
were derived from a mid-exponential phase culture. Sam-
ples were taken at 0, 24, 44, and 118 hours for analysis of
apoptosis.
Transfection with the hSEAP-hFc gene
The plasmid, pFUSE-SEAP-hFc1, (InvivoGen, USA) was
used to transfect cMycCHO and CHO-K1 cell lines using
FuGENE® 6 transfection reagent (Roche, UK). Transfected
cells were incubated in fresh DMEM/F12 (Sigma-Aldrich)
with 5% heat inactivated FBS (PAA, UK) and 4 mM L-
glutamine or 4 mM L-alanine-L-glutamine (Ultra-
Glutamine, Lonza, UK) at a temperature of 37°C vented
at 5% CO2. The culture medium was then replaced with
fresh medium containing 400 ug/ml Zeocin™ and incu-
bated at 37°C. After 3 days the transfected cells were
selected in fresh medium containing 400 ug/ml Zeocin™
and 1 mg/ml G418 followed by isolating the population
of cells by limiting dilution. Selection of stable clones was
done by assessing for the highest SEAP activity for each
cell line over a period of 6 weeks. To ensure that expres-
sion remained stable the cultures were cultured in the
presence of G418 and Zeocin™ every 10th generation.
Western Analysis
Total cellular protein was prepared from cells washed in
0.35 M sucrose and resuspended in 400 μl of lysis buffer
(Ultrapure reagents from Amersham Biosciences, Piscata-
way, NJ): 2% (w/v) CHAPS, 9.5 M urea, 0.8% (w/v) phar-
malyte pH 3-10, 1% (w/v) DTT (Amersham Biosciences,
UK) and 1 protease inhibitor tablet per 10 ml (Roche
Molecular, Mannheim, Germany) for 30 minutes before
subsequent 4°C centrifugation at 17,000 g for 30 min-
utes. Sample was stored at -80°C for minimum of 24
hours before concentration determination using a modi-
fied Bradford assay [13]. 50 μg/well underwent electro-
phoresis on a 12% sodium dodecyl sulfate-
polyacrylamide (SDS-PAGE) mini gel (Pierce, Rockford,
IL) after dilution in 1× Laemli buffer prior to denaturation
at 95°C for 10 minutes. The gel was stained with Instant-
blue™ (Novexin Ltd, UK) for visual verification of loading
before de-staining for electrotransfer. The protein was
then transferred to nitrocellulose membrane (Amersham
Biosciences, Little Chalfont, UK). Then, the membrane
was incubated with the primary antibody, anti-myc 9E10
antibody (Santa Cruz Biotechnology, Santa Cruz, CA),
and then incubated with a HRP conjugated anti-mouse
whole IgG from goat as the secondary antibody. Bands
were developed by chemiluminescent detection (Super-
Signal West Pico System, Pierce) according to the manu-
facturer's instructions. The membrane was stained with
Ponceau S to re-verify loading and uniformity of the elec-
trotransfer.
Static Cell Cycle Data
Flow cytometry was used to determine the percentage of
cells in various phases of the cell cycle. Every 24 hours
both CHO-K1 and cMycCHO were dissociated from the
wells using Accutase™, centrifuged at 160 g for 5 minutes
and were resuspended in 500 μl of Nuclear Isolation
Media (NIM)-DAPI staining solution (NIM-DAPI, NPE
Systems, Pembroke Pines, FL, USA) at a density of 1 × 106
cells/ml for 1 minute at room temperature. The suspen-
sion was then filtered through a 25 μm Filter Tip (NPE
Systems). NIM-DAPI stained samples were run on a Beck-
man Coulter Quanta SC flow Cytometer fitted with a mer-
cury arc lamp, a 357/22 nm exciter and a 465/30 nm
emission filter. The G1 peak was fixed at a specific channel
number and a minimum of 15,000 nuclear signals was
collected. The distribution of cells in the G1, S, and G2/M
phases was analyzed with the Multicycle software pro-
gram (Phoenix Flow Systems, San Diego, CA).
Analysis of Apoptosis
CHO-K1 and cMycCHO cells removed at different times
during the batch cultures and cells incubated in spent
media were analysed for the percentage of viable, apop-
totic and necrotic cells. Dual staining for both Annexin-V
binding to phosphatidylserine (PS) surface proteins by
Annexin-V- Fluorescein isothiocyanate (FITC) (BD Bio-
sciences, UK) and cellular DNA using Propidium Iodide
(PI) was performed as follows (Ishaque and Al-Rubeai,
1999): 1 × 106 cells/ml were washed in ice cold PBS (0.01
M phosphate buffer, 0.0027 M potassium chloride and
0.137 M sodium chloride, pH 7.4, at 25°C) and centri-
fuged at 300 g for 5 minutes at 4°C for resuspension in 1×
binding buffer ((10 mM HEPES solution) pH 7.4, 140BMC Biotechnology 2009, 9:76 http://www.biomedcentral.com/1472-6750/9/76
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mM NaCl, and 2.5 mM CaCl2). 1 μl of Annexin-V FITC
was added to 100 μl of cell suspension and incubated for
10 minutes at 20-25°C before adding 400 ul of 1× bind-
ing buffer and 10 μl of PI (50 ug/ml) which was incubated
for 1 minute before analysis. The sample was analysed
with a Beckman flow cytometer equipped with a 488 nm
diode laser. A 525 band pass detection filter was used to
obtain FITC fluorescence and a 670 nm long pass filter is
used to collect the maximal emission of PI fluorescence
[14]. Fluorescence compensation was carried out before
taking final readings.
Cell Cycle Kinetics Labelling
A BrdU (5-Bromo-2'-deoxyuridine) pulse labelling and
staining procedure for kinetic analysis of the cell cycle was
initiated the 2nd day after initial seeding of the cultures in
flasks. 20 μM of BrdU (BD Biosciences, UK) was added to
the exponentially growing cells. After a labelling pulse of
1 hour at 37°C, cells were washed with fresh medium and
then incubated in the corresponding medium for 1, 3, and
5 hours with samples taken from triplicate wells. After the
indicated BrdU-free chase time, cells were harvested and
washed twice in ice-cold PBS and centrifuged at 500 g for
5 minutes. The cells were then resuspended in 500 μl ice-
cold PBS and 5 ml 70% ethanol was added drop-wise
before leaving the suspension on ice for 15 minutes. The
samples were stored in a -20°C for 1 week after fixation.
The staining procedure to determine the DNA and BrdU
content was a modified procedure from Istfan N.W et al.
[15]. Briefly, the fixed samples were centrifuged for 10
minutes at 500 g and then washed twice with cold PBS. To
this 3 ml of 2N HCl was added and left at room tempera-
ture in the dark on a shaker for 30 minutes before washing
with PBS and then adding 3 ml of 0.1 M Borax to neutral-
ize the acid at room temperature for 2-4 minutes. 3 ml of
0.5% Triton X-100 was added and left for 10 minutes at
room temperature on a shaker after a PBS wash. After-
wards, the pellet was resuspended in 0.1 ml of PBS and 20
μl of anti-BrdU FITC (BD Bioscience) was added directly
before incubation for 30 minutes at room temperature in
the dark. The sample was then washed with PBS and the
pellet resuspended in 0.5-1 ml of PBS before adding 50 μl
of RNase A solution per tube and incubated for 30 min-
utes at 37°C. From a 1 mg/ml stock, 25 μl of PI stain solu-
tion was added per tube and left on ice for 30 minutes
before bivariate DNA-BrdU analysis was carried out on
the flow cytometer.
Cell Cycle Kinetic Analysis
Dual stained samples were analysed with a Beckman flow
cytometer equipped with a 488 nm diode laser, A 525
band pass detection filter was used to obtain green fluo-
rescence from FITC-labeled anti-BrdU and a 670 nm long
pass filter is used to collect the maximal emission of PI red
fluorescence. The red fluorescence was calibrated by set-
ting the G1 peak to a fixed channel number and green flu-
orescence was calibrated using an unlabeled control. The
cell size was also taken simultaneously at 48 and 53 hours
(exponential phase) with these samples to determine the
relative cell size in each phase. Cell Lab Quanta SC soft-
ware (Beckman Coulter, UK) and the computer program
WinMDI V2.8 (The Scripps Research Institute) was used to
analysis the cytometric histograms. Calculations was car-
ried out using the equations previously described [16-18].
Briefly, the bivariate BrdU-DNA contour plot obtained
with WinMDI V2.8 had the cells separated on the x-axis
according to DNA content and the y-axis according to
BrdU incorporation. Gating was established for G1, G2/M,
labeled undivided (flu) cells, and labeled divided (fld)
cells. First, the relative movement (RM) at each pulse time
point of the cells during the S-phase to G1 and G2 was cal-
culated using the following equation:
Where FL(t) is the mean red fluorescence at time (t) while
FG1 and FG2+M are the mean red fluorescence of cells in
each respective phase. This can be related to the following
linear relationship:
Second, the function v [16] a quantity (= cTS) represented
by the following equations is obtained:
&
Equation 3a is used when the times are less than the time
for the G2+M  phase (TG2+M) and equation 3b other-
wise[16]. Here the fraction of labeled undivided (flu),
labeled undivided in G2+M phase (flu
G2+M), and labeled
divided (fld) are obtained from the bivariate BrdU-DNA
contour plot.
The potential cell cycle time (Tpot)[15] can be calculated
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To determine the calculated time for the cell spent in G2
and M phase an analytical procedure described in White
et al, 2000 was used. This relies on the calculation of the
solution to a cubic equation where the cell production
rate (c) is obtained through a relation between RM(t), v,
and flu[18]:
Where
After determining the cell production rate the following
equation is used to determine TG2+M:
After determining TG2+M and TS the time spent in G1 could
be calculated by subtraction of both calculated times from
Tpot.
Determination of Extracellular Glucose, Lactate, 
Ammonia and Amino Acid Concentrations
Glucose was measured with an Ascencia contour (Bayer
Diagnostics, Ireland) glucose meter with the provided pre-
calibrated Microfill test strips (Bayer Diagnostics, Ire-
land). Lactate was measured using the Accutrend Lactate
Meter together with BM-Lactate Strips (Roche Diagnostics
GmbH, Germany). Briefly, The BM-Lactate calibration
strip was used to calibrate the instrument to the accompa-
nied BM-Lactate strips. Lactate was determined by reflect-
ance photometry at a wave length of 657 nm via a
colorimetric-oxidase mediator reaction. L-Glutamine and
ammonia were measured with a Megazyme kit K-ASNAM
(Megazyme, Ireland) using supernatant from each day of
the culture. The amino acids samples were taken at the
end of exponential phase by centrifuging 1.5 ml of culture
for 5 minutes at 180 g and storing the supernatant at -
20°C for 1 week before analyses. Amino acids were ana-
lysed by Alphalyse (Denmark) and performed on a Bio-
chrom™ amino acid analyzer.
Reporter Assay
The hSEAP-hFc reporter constructs containing the SEAP
gene were analyzed using the QUANTI™-Blue™ SEAP
Reporter System (Invivogen), which detects SEAP enzyme
activity. Instead of a single reading after a determined
period of time, multiple reads were taken at 1 min inter-
vals for 20 minutes, after 30 minutes of incubation at
37°C, and used to express SEAP activity as absorbance
units per second (abs/sec). The SEAP activity was normal-




Figure 1a shows the growth curve of cMycCHO compared
to CHO-K1. The adherent cMycCHO culture showed a sig-
nificant increase in overall proliferative capacity being
able to proliferate to a cell density of 1.99 × 106 cells/ml,
a 72% increase in density versus the control CHO-K1. The
viability remained above 90% for both cell lines through-
out the culture until day 6 when the CHO-K1 viability fell
just below 90% compared to 95% from the cMycCHO
culture. The growth rate increased from 0.017 hours-1, for
CHO-K1, which is comparable to reported rates of other
adherent CHO cultures [3,20,21], to 0.023 hours-1, for
cMycCHO. This resulted in a doubling time decrease of
25.4% while the integral viable cell (IVC) increased from
4.34 × 109 cell day L-1 to 6.87 × 109 cell day L-1 for the
CHO-K1 and cMycCHO, respectively for the period of 5
days. From current and previous work it is seen that cMy-
cCHO cells have a different morphology in adherent cul-
ture to CHO-K1. This is further investigated by measuring
cell size. Contact inhibition may be a factor, as well, in
determining cell number but in this case both cell lines
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Batch cultivation of cMycCHO Figure 1
Batch cultivation of cMycCHO. The growth curve (a) of 
cMycCHO (grey circles) compared to CHO-K1 (Black 
squares). This culture seeded and grown (n = 3) in parallel, as 
a control for the BrdU pulse labeled cultures shows that 
cMycCHO (maximum cell density 1.99 × 106 cells/ml) has an 
increased proliferation capacity compared to the CHO-K1 
(maximum cell density 1.1 × 106 cells/ml). (b) Western analy-
sis of biological duplicate samples with c-Myc over-expres-
sion observed in the cMycCHO cell lines.BMC Biotechnology 2009, 9:76 http://www.biomedcentral.com/1472-6750/9/76
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in IVC would be an advantage in bioprocess systems
where the increase in overall maximal cell number usually
associated with more product formation if cell production
rate is not significantly decreased.
The constitutive over-expression of c-myc, has clearly
resulted in an overall increase in proliferation rate but also
an increased maximal cell number under batch condi-
tions. Increased proliferation would mean that cell divi-
sion has increased or apoptosis has decreased or both. The
fact that c-myc has been shown to be a potent inducer of
apoptotic cell death in mammalian cells [11] in contrast
to the viability data obtained in this work warrants further
studies to explore the control mechanism of cell growth/
death kinetics.
In addition, in order to confirm that the over-expression
of the c-Myc protein was still present after thawing the cell
line a western blot was done from duplicate cultures
derived from the experimental seeding inoculum and
grown to mid-exponential phase to obtain the superna-
tant for analysis shown in Figure 1b.
Cell Cycle
The cell cycle distribution of cMycCHO cells in Figure 2
clearly shows a consistent increased proportion of post G1
phases over the control (on average >10% increase in S
phase cells). However, at the end of the batch cultures
both cultures showed an increase in G1 cells indicating a
decline in proliferation rate presumably due to increasing
environmental stress resulting from nutrient deprivation
and accumulation of toxic metabolites. Previously, it was
shown in CHO cultures that the proportion of S phase
cells enables prediction of changes in cell number and
reflects the proliferation dynamics of cell culture [22]. It
may be reasonable to suggest that the increased growth
rate of cMycCHO is a consequence of increased propor-
tion of S phase cells.
Figure 3a is a representative bi-variate contour plot at 5
hours after pulse labelling during exponential phase illus-
trating cells in G1 and G2/M phase as well as the undivided
(flu) and divided (fld) fractions. From the plots the relative
movement of labeled undivided cells as a function of time
was calculated and a linear regression analysis was applied
to determine the cell cycle times (Figure 3b). The values
for TS were similar for both cultures but when the poten-
tial cell cycle time (Tpot) was calculated, cMycCHO
showed a significantly faster time. Subsequently the time
spent in G1 phase was found to decline by 36.4% in cMy-
cCHO which pertains to the increased proliferation rate
observed. It was obvious that the increase in proliferation
rate of cMycCHO was due to a decreased cell cycle time via
a shortened G1 phase. The finding of this work is in agree-
ment with previous work showing that deletion of the c-
myc gene impedes cell cycle progression thus retarding
cell proliferation [23,24]. More importantly, the analysis
gives a clear indication that c-myc  over-expression
enhances cell proliferation by promoting the earlier G1-S
transition, by shortening the G1 phase of the cell cycle. It
appears that once the cell progresses to S phase of the cell
cycle the time to cell division remains unchanged.
Cell Size
Throughout the exponential phase of the cell culture the
cell size of cMycCHO is shown to be smaller than the con-
trol. Quantifying the relative cell size difference for each
phase of the cell cycle it is shown that the exponential
growth occurs with cMycCHO having a smaller size
throughout (Figure 4). With an average cell diameter of
12.16 μm and 14.11 μm respectively (Figure 5), While
this represents a 36% decrease in cell volume, it indicates
a difference in the mean volumetric biomass (a function
of the cell volume and maximum cell density) of 1:0.9
nm3 cells ml-1 for cMycCHO:CHO-K1, a rather minor dif-
ference in comparison to the >70% difference in cell
number.
Beier et al. (2000) suggested that c-myc over-expression
may control cell size [25]. However, Trumpp et al. (2001)
argued that c-myc controls cell number and not the cell
A histogram of the cell cycle phases for cMycCHO versus  CHO-K1 culture Figure 2
A histogram of the cell cycle phases for cMycCHO 
versus CHO-K1 culture. cMycCHO is represented by the 
non-shaded cell cycle profile (blue profile line) while the 
CHO-K1 profile represented by a shaded area underneath 
the histogram. It can be seen that the percentage frequency 
of the G1/G0 region in the 200 channel emission spectra 
decreases below CHO-K1 as the culture progresses while 
the S-phase (between 200 and 360 emission channel) and G2/
M (at ~360 emission channel) is consistently greater with cul-
ture time for cMycCHO.BMC Biotechnology 2009, 9:76 http://www.biomedcentral.com/1472-6750/9/76
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size. Indeed, fibroblasts have shown no need for c-myc
activity for increasing cell size but such activity was neces-
sary for G1-S transition [26]. Other studies have reported
varied results for the relationship between c-myc and cell
size. For example, hepatocytes with c-myc overexpression
have shown an increased cell size in one study [27] and
reduced cell size in another study [28]. An increase in cell
size may well depend on the stoichiometric molar con-
centrations of c-myc  leading to the cell size increase
through the simulation of mTOR via inhibition of TSC2
[29], which might be the case in some cancers. While
CHO cells have many similarities to cancerous cells the
contrasting results of decreasing cell size may not find
explanation in mTOR pathway and protein synthesis.
However, it is not unreasonable to suggest that such a sig-
nificant change in size would involve a major change in
the metabolic consumption and secretion state of the
cells, since the cell's ability to either get substances from
the outside, or eliminate waste, is related to the surface
area. Since the increased cell number of cMycCHO was
independent of nutrient availability the concentration of
necessary nutrients and energy required for maintenance
and proliferation should be reduced if apoptosis is not
enhanced; a suggestion is investigated below. It may be
interesting to note that when a cell enters the cell cycle it
has to reach a critical mass before proceeding to S phase.
This work shows that c-myc can cause a reduction in the
required critical mass for the transition into S phase by
decreasing protein content (data not included) in addi-
tion to cell size. This suggests a decoupling of cell size
from cell division, a phenomenon that has been also
observed in stem cells and neurons, and in addition, ele-
vated G1 cyclin levels in fibroblast cells can cause elimina-
tion of restriction point control resulting in smaller small
cell size [30,31].
Metabolites
Table 1 shows the specific consumption and production
rates of several metabolites. Glucose analysis revealed that
cMycCHO had a 40% decrease in specific glucose con-
Cell cycle kinetics analysis Figure 3
Cell cycle kinetics analysis. Example of the contour plot 
obtained 5 hours after BrdU pulse labelling cMycCHO cul-
ture (a). The plot displays the DNA content (x-axis) and 
BrdU-FITC fluorescence intensity (y-axis). Four regions can 
be observed with the G1 and G2/M phase represented by the 
DNA content shift while the BrdU labeled undivided cells 
undergo a temporal shift from the region above G2/M to the 
region above G1, indicated as the labeled divided cells on the 
plot. The bar chart (b) represents the cell cycle phase times: 
TG1, TS, TG2+M, and Tpot (n = 3). Unpaired Student's t-
test indicates TG1 and Tpot are significantly different 
between cMycCHO and CHOK1 (p < 0.05).
Cell size at different cell cycle phases for cMycCHO (right  bar) versus CHO-K1 (left bar) at 48 and 53 hours of the  exponential phase culture with n = 3 Figure 4
Cell size at different cell cycle phases for cMycCHO 
(right bar) versus CHO-K1 (left bar) at 48 and 53 
hours of the exponential phase culture with n = 3. The 
third set is a combination of both samples to illustrate the 
smaller cell size of cMycCHO from G1 and carried through-
out the cycle.BMC Biotechnology 2009, 9:76 http://www.biomedcentral.com/1472-6750/9/76
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sumption rate. This decreased value is associated with the
decrease in specific lactate production rate (43%).
Glutamine consumption was also decreased by 42%
while ammonia production showed only a slight increase
of 9%. Lactate/glucose molar yield coefficient has
remained relatively similar in both cell lines, but the yield
coefficient for ammonia from glutamine has increased by
47% mainly due to the decrease in glutamine consump-
tion rate. The increased ammonia production is conso-
nant with the view that alanine is metabolised to form
glutamate, which is subsequently deaminated oxidatively
to liberate ammonia. The association of such an increase
with c-myc is not clear but lower rate of glutamine con-
sumption is consistent with lower maintenance energy
requirement by cells at higher growth rates.
Individual amino acid consumption rates, shown in Fig-
ure 6, display an overall reduction in amino acid uptake
at the end of exponential phase of cMycCHO culture. The
highest decrease in amino acid consumption rate is seen
for glutamate, with 65% decrease in consumption. The
difference in total amino acid consumption rate is approx-
imately 2.2 fold apart from glutamate (2.8 fold) and
Electronic cell volume distributions (arbitrary units) of cMycCHO (red line) and CHO-K1 (green, shaded) cell lines (n = 3)  from early-24 hours (a), mid-72 hours (b) to late-96 hours(c) exponential phase Figure 5
Electronic cell volume distributions (arbitrary units) of cMycCHO (red line) and CHO-K1 (green, shaded) cell 
lines (n = 3) from early-24 hours (a), mid-72 hours (b) to late-96 hours(c) exponential phase.
Table 1: Specific rates for glucose, lactate, l-glutamine, and 
ammonia for cMycCHO and CHO-K1 cell lines.
Parameters for CHO Cell Culture
CHO-K1 cMycCHO
qGlc(μmol 10-6 cell day-1)* 6.25 3.74
qLac(μmol 10-6 cell day-1) 6.50 3.72
qGln(μmol 10-6 cell day-1)* 0.88 0.51
qAmm(μmol 10-6 cell day-1) 0.59 0.65
Y 'Lac/Glc(mol/mol) 1.04 0.99
Y 'Amm/Gln(mol/mol) 0.67 1.27
* Consumed metabolite
Amino acid consumption in cMycCHO cell line as a percent  of the control cell line illustrated by the ratio of amino acids  consumed per cell at the end of the exponential growth  phase (day 5) Figure 6
Amino acid consumption in cMycCHO cell line as a 
percent of the control cell line illustrated by the ratio 
of amino acids consumed per cell at the end of the 
exponential growth phase (day 5).BMC Biotechnology 2009, 9:76 http://www.biomedcentral.com/1472-6750/9/76
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alanine (1.8 fold). The lower fold change for alanine and
increased fold change in glutamate may be related to a dif-
ference in alanine transaminase reaction between the two
cell lines, where cMycCHO has an increase in the amount
of nitrogen being incorporated into alanine [32]. The by-
product of this reaction is pyruvate which can be used in
glycolysis to lower glucose consumption and lactate pro-
duction [33,34]; an explanation supported by the current
metabolic data (Table 1). Moreover, the lowered meta-
bolic burden of a smaller cell size may also offer an expla-
nation to the reduced metabolic requirements of the
cMycCHO cells. It may also possible that the decreased
cell volume could mean that the energy requirements to
sustain other protein synthetic machinery, not essential
for cell survival, have also decreased.
Additionally, since the mTOR pathway and c-Myc protein
are affected upstream by AKT [35,36], over-expression of
c-Myc protein will bypass this pathway and partly decou-
ple the simultaneous effect on both growth and prolifera-
tion. Thus, since c-Myc initiates entrance into S-phase, by
acting as a transcription factor for several cell cycle genes
such as cyclin D2 and CDK2 [9], and since the mTOR
pathway suggests the same AKT activation from the exter-
nal environment as the control, cell size would not
increase with increased proliferation thus decreasing the
overall cell size distribution.
These studies together with the current data suggest that
the decreased influx of amino acid is a consequence of the
decreased critical mass required to enter S-phase. In lim-
ited cellular resources c-myc forces the cell to progress pre-
maturely into S phase.
Apoptosis
The data in Figure 7 demonstrates that apoptosis plays a
minimal part in determining the cell number during the
growth phase. Contrary to previous results the cMycCHO
Apoptosis of cMycCHO compared to CHO-K1 cultures in exponential growth (a) and spent medium (b) Figure 7
Apoptosis of cMycCHO compared to CHO-K1 cultures in exponential growth (a) and spent medium (b). Cells 
were analysed by staining with Annexin V-FITC and PI for counting viable (none stained), early apoptotic (Annexin V-FITC 
staining), late apoptotic (both Annexin V-FITC and PI staining) and necrotic cells (PI staining only) at 0, 25, 44, and 118 hours. 
Under t-Test criteria, p < 0.05 for viable and apoptotic cells with n = 3. Spent medium was obtained from the end of the death 
phase of batch culture. Cells from both cell lines were incubated in spent medium for up to 118 hrs.BMC Biotechnology 2009, 9:76 http://www.biomedcentral.com/1472-6750/9/76
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cell line showed a slight decrease in apoptosis during the
growth and decline phase of cell culture in comparison to
the control. The data demonstrated that c-myc did not sen-
sitised the cells to apoptosis stressors. The data are consist-
ent with the control and c-myc over-expressed cells being
equally killed by apoptosis at the later stage of cultures.
Quantification of apoptosis in spent media cultures (Fig-
ure 7b) gave similar results to the batch culture where a
minimal difference was observed between the two cell
lines. After 118 hours in spent media both cell lines had
38% of late apoptotic cells in culture. Thus, it is most
unlikely that c-myc plays any role in CHO apoptosis which
triggers in cell culture by nutrient depletion and environ-
mental chemical stresses [37-40].
Cell Growth and hSEAP-hFc Production
To understand if a transfected and selected stable popula-
tion of cMycCHO cells can affect the general production
of a fusion SEAP compared to the CHO-K1 population,
the cells were analysed for production capability. Upon
transfection with a hSEAP-hFc construct and selection of
the cMycCHO cell line population, the procedure pro-
duced a cell line with an increased maximal cell density
(CHO95, using the c-myc over expressing cell line) com-
pared to the control CHO80 as can be seen from the
resultant growth curves (Figure 8a). The transfected CHO-
K1-hSEAP-hFc (CHO80) remained at a lower maximal
cell number of 1.37 × 106 cells/ml compared to the 1.69 ×
106 cells/ml reached by CHO95. The growth rate between
the cell lines has a difference of 4.4 hours in the doubling
times with CHO95 obtaining the fastest doubling time of
34 hours with high confidence of p < 0.05 using the Stu-
dent's  t-Test. This result shows that in the two stably
selected cells, the c-myc gene bestows greater proliferation
even with the extra metabolic burden of recombinant pro-
tein production.
The hSEAP-Fc activity was measured to be greatest
throughout the culture supernatant for CHO80 (See Fig-
ure 8b), thus the secretion of properly functioning hSEAP-
hFc was higher in this cell line. The assay used the kinetics
of hSEAP-hFc to determine activity rate via linear regres-
sion analysis obtaining an indirect measurement of pro-
ductivity. As can be seen only on day 11 of the culture,
when CHO80 has entered the death phase, and CHO95 is
in stationary phase, the amount of hSEAP-hFc activity for
each population is within 0.7% of each other while the
relative specific productivity of CHO95 is 87.38% of
CHO80. This indicates that the CHO95 cell line with c-
myc  over-expression has lower hSEAP-hFc productivity.
There appears to be a consequence to the increased
growth profile of c-myc expressing CHO cells which is a
reduction in the rate of active hSEAP-hFc production.
Conclusion
While over-expression of c-Myc reduces the transition
time of G1 phase to S, the resultant reduction in the critical
mass required for this earlier transition to occur negatively
affects the maximal volumetric biomass achieved in cul-
ture. In addition, the overall metabolic energy pathways
are modified to decrease glucose and glutamine consump-
tion rate which might explain the resultant increase in
maximal cell density in the absence of nutrient supple-
mentation. The shortening of the G1 phase by c-myc over-
expression allowed the cells to have higher growth rate
Batch Cultivation of CHO95 versus CHO80 Figure 8
Batch Cultivation of CHO95 versus CHO80. This is 
represented by the growth curve (a) of CHO80 (blue dia-
monds) and CHO95 (green circle) cell line (n = 3) including 
the (b) SEAP activity of CHO80 (yellow bar) versus CHO95 
(brown bar) measured from the supernatant by kinetic analy-
sis of 625 nm absorbance through 60 second intervals for 50 
minutes for time points representing the culture progression 
from exponential phase to the start of the death phase.BMC Biotechnology 2009, 9:76 http://www.biomedcentral.com/1472-6750/9/76
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while reducing cell size allowing cells to achieve higher
cell numbers. Apoptosis was shown to be unaffected by c-
myc, in contrast to previous reported results but produc-
tion of hSEAP-hFc from a constitutive c-myc over-express-
ing cell line did not increase with the increase in cell
number.
This report clearly demonstrated that by manipulation of
the cell cycle kinetics, and indirectly its metabolic path-
ways, it is possible to reach higher cell densities in batch
cultures with limited nutrients. However, the effect on
recombinant protein production due to the smaller cell
size and reduced metabolite consumption will need to be
further investigated to establish c-myc usefulness in bio-
logics production.
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